AMYLIN + GLP-1 RECEPTOR AGONISM
Cagrilintide + Semaglutide
A co-administered formulation concept combining cagrilintide and semaglutide; evidence for the combination should be distinguished from evidence for either constituent alone.
At a Glance
PRIMARY RESEARCH AREAS
Amylin and GLP-1 signaling; appetite and energy intake; body-weight research; metabolic physiology
EVIDENCE LEVEL
Human clinical evidence exists for the combination; interpretation should remain specific to the studied formulation and trial context.
This profile provides an evidence-first overview of Cagrilintide + Semaglutide. Human clinical evidence exists for the combination; interpretation should remain specific to the studied formulation and trial context.
Overview
A co-administered formulation concept combining cagrilintide and semaglutide; evidence for the combination should be distinguished from evidence for either constituent alone. Interpretation remains limited to evidence attributable to the exact compound or formulation.
Research Context
Clinical development of coadministered cagrilintide and semaglutide has focused primarily on overweight and obesity, including populations with and without type 2 diabetes. The REDEFINE clinical program provides direct randomized controlled evidence for the combination, allowing it to be evaluated as a studied intervention rather than relying solely on extrapolation from evidence concerning each component individually.
Mechanism / Biological Context
Overlapping research areas provide a rationale for studying the constituents together, but they do not establish additive or synergistic effects.
Published Research
Evidence for GLOW should be read as separate GHK-Cu, BPC-157, and thymosin beta-4 / TB-500 contexts rather than as evidence for a single tested product. The concise evidence matrix below summarizes the cellular, preclinical, and human landscape.
Limitations / What Remains Unknown
Important areas for continued study include longer-term safety and durability of outcomes, maintenance following treatment changes, population-specific responses, cardiovascular and other clinical outcomes, and the relative contribution of each component to outcomes observed with coadministration. Findings from controlled trials should not automatically be generalized beyond the studied populations, formulations, endpoints, and trial conditions.
References
Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2025;393:635–647. DOI: 10.1056/NEJMoa2502081. Davies MJ, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine. 2025;393:648–659. DOI: 10.1056/NEJMoa2502082.
References and claims are limited to evidence that can be verified for the exact compound or formulation.
Evidence Landscape
Evidence involving individual constituents should be interpreted according to the exact compound, formulation, route, population and endpoint studied. Controlled human evidence specifically evaluating the combined 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 formulation has not been established.
CELLULAR / IN-VITRO EVIDENCE
Mechanistic evidence supports distinct amylin- and GLP-1-receptor signaling pathways. Cellular findings provide biological context but should not be interpreted as direct evidence of clinical outcomes from the combination.
ANIMAL / PRECLINICAL EVIDENCE
Preclinical research has contributed to understanding amylin and GLP-1 biology and the rationale for complementary pathway activation. Human clinical outcomes should be evaluated independently from preclinical findings.
Human Evidence
Direct human evidence includes large randomized Phase 3 trials evaluating coadministered cagrilintide and semaglutide in adults with overweight or obesity, including populations with and without type 2 diabetes. Outcomes studied include body-weight change, glycemic measures, cardiometabolic variables, adverse events, and tolerability.
Key Findings by Research Area
Body-weight regulation is currently among the most extensively characterized clinical research areas for the combination. Randomized trials have also evaluated glycemic outcomes, cardiometabolic measures, and tolerability. Findings should be interpreted according to the population, endpoint, and estimand used in each trial.
Safety & Tolerability Evidence
Gastrointestinal adverse events were the most frequently reported events in Phase 3 studies. Safety findings should be interpreted within the populations, duration, doses, and conditions evaluated in those trials. Longer-term safety continues to require evaluation.
Research Gaps & Interpretation
Continued research is needed to characterize longer-term outcomes, durability, cardiovascular and other clinical endpoints, broader population generalizability, and the relative contribution of each component. Evidence concerning semaglutide or cagrilintide individually should not automatically be attributed to their coadministration.
Editorial Review
EDITORIALLY REVIEWED
LAST REVIEWED
Research profile reviewed for source accuracy, evidence classification, and distinction between preclinical, mechanistic, and human evidence.